Related Experiment Video
Updated: Aug 17, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
Mutational analysis of PRKAR1A and Gs(alpha) in sporadic adrenocortical tumors
R Libé1, G Mantovani, S Bondioni
1Institute of Endocrine Sciences, University of Milan, Ospedale Maggiore IRCCS, Milan, Italy.
Abstract:
Little is known about the pathogenesis of adrenocortical tumors. The cAMP-dependent pathway is physiologically activated by ACTH in adrenocortical cells and different components of this cascade may be altered in some functioning adrenocortical tumors. Recently, mutations of the gene encoding the PKA type 1 A regulatory subunit (R1 A), PRKAR1A, associated with loss of heterozygosity (LOH) at PRKAR1A locus, have been demonstrated in primary pigmented nodular adrenocortical disease (PPNAD), either isolated or associated with Carney complex. Moreover, activating mutations of the Gs(alpha) gene (the gsp oncogene) have also been found in a small number of adrenocortical cortisol-secreting adenomas. Aim of this study was to investigate the presence of such genetic alterations on a series of 10 ACTH-independent Cushing syndrome due to non-PPNAD adrenocortical adenomas. The coding sequence of PRKAR1A, evaluated by PCR and direct sequencing analysis, revealed the absence of mutations while heterozygosity for at least 1 polymorphism excluded LOH in most tumors. In one single adenoma gsp mutation was detected. In conclusion, we provide additional evidence that the only mutational changes able to activate the cAMP pathway so far identified, i.e. PRKAR1A mutations and gsp oncogene, are a rare event in adrenocortical tumors.
Insights
Genetic mutations in the cAMP pathway, including PRKAR1A and gsp oncogene, are rare in adrenocortical tumors causing Cushing syndrome. This study found no PRKAR1A mutations and only one gsp mutation in tested samples.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Adrenocortical tumor pathogenesis is poorly understood.
- The cAMP pathway, activated by ACTH, is implicated in some functioning tumors.
- PRKAR1A mutations and gsp oncogene mutations are known alterations in specific adrenocortical conditions.
Purpose of the Study:
- To investigate PRKAR1A mutations and loss of heterozygosity (LOH) in ACTH-independent Cushing syndrome.
- To screen for gsp oncogene mutations in non-PPNAD adrenocortical adenomas.
- To determine the frequency of these specific genetic alterations in this tumor cohort.
Main Methods:
- PCR and direct sequencing to analyze the PRKAR1A coding sequence.
- Evaluation of heterozygosity for polymorphisms to assess LOH at the PRKAR1A locus.
- Genetic analysis of 10 ACTH-independent adrenocortical adenomas.
Main Results:
- No mutations were detected in the PRKAR1A gene across the analyzed tumors.
- Heterozygosity for polymorphisms indicated the absence of LOH in most samples.
- A single case of gsp mutation was identified in one adenoma.
Conclusions:
- PRKAR1A mutations are not a significant factor in this cohort of ACTH-independent Cushing syndrome.
- Gsp oncogene mutations are also infrequent in non-PPNAD adrenocortical adenomas.
- The identified genetic alterations activating the cAMP pathway are rare in adrenocortical tumors.
Related Concept Videos
The Ras Gene
Ras is a superfamily...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase